GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TWi Biotechnology Inc (ROCO:6610) » Definitions » ROE % Adjusted to Book Value

TWi Biotechnology (ROCO:6610) ROE % Adjusted to Book Value : -12.32% (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is TWi Biotechnology ROE % Adjusted to Book Value?

TWi Biotechnology's ROE % for the quarter that ended in Jun. 2024 was -66.03%. TWi Biotechnology's PB Ratio for the quarter that ended in Jun. 2024 was 5.36. TWi Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -12.32%.


TWi Biotechnology ROE % Adjusted to Book Value Historical Data

The historical data trend for TWi Biotechnology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TWi Biotechnology ROE % Adjusted to Book Value Chart

TWi Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.57 -8.58 -1.39 -6.43 -17.38

TWi Biotechnology Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.22 -6.86 -5.40 -28.61 -12.32

Competitive Comparison of TWi Biotechnology's ROE % Adjusted to Book Value

For the Biotechnology subindustry, TWi Biotechnology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TWi Biotechnology's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TWi Biotechnology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where TWi Biotechnology's ROE % Adjusted to Book Value falls into.



TWi Biotechnology ROE % Adjusted to Book Value Calculation

TWi Biotechnology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-62.41% / 3.59
=-17.38%

TWi Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-66.03% / 5.36
=-12.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TWi Biotechnology ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of TWi Biotechnology's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


TWi Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
Lane 221, Kang Chien Road, 8th Floor, Number 41, Neihu District, Taipei, TWN, 11494
TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs for unmet medical needs, particularly in the diseases associated with innate immunity. The pipeline products of the company comprise AC-201, AC-203, and AC-701.

TWi Biotechnology Headlines

No Headlines